SAFC plans a $12 million expansion at its biologics production facility in Carlsbad, CA. Two fully segregated viral product manufacturing suites will be built. They will enable an increase in SAFC Pharma’s viral manufacturing capacity to commercial-scale quantities, explains vp of manufacturing and U.S. operations, David Feldker.
Due to become operational in the second half of 2009, the new facilities will add 8,000 sq. ft. of manufacturing space and enable 100 L batch production in stirred tank bioreactors and 1,000 L batch manufacturing in disposable bioreactors, continues Feldker.
The expansion will add to the current 44,000 sq. ft. site and be Biosafety Level 2 compliant, allowing manipulation of human pathogens.